Is Viable Cannabis Seed Inside the Schedule III Carve-Out?

Here is a sentence from federal law that almost no one quotes in Schedule III coverage. Under 21 U.S.C. 802(16), the marijuana definition excludes mature stalks, fiber, oil or cake made from the seeds, and the sterilized seed of the plant that is incapable of germination. Read that last clause the way a lawyer would. A seed that can germinate is not excluded. In the statute's eyes, it is the plant.

The April 2026 order partially moved marijuana to Schedule III, covering state-licensed medical marijuana. Nearly all the coverage that followed has been about dispensaries, products, taxes and registration. My argument is narrower and, I think, more useful to anyone who grows: whether that order reaches viable seed and clones is a question of text, and the headlines have not asked it. Seedtiva's own coverage has followed the same downstream path, and this piece tries to look upstream, at the seed and the clone.

The primary documents are public: the DOJ announcement of April 23-24, 2026 and the Federal Register notice of April 28. I am reading them against the statute. One caveat up front. This is a reading and a list of questions for a regulator or counsel, not legal advice, and legality varies by state. Where I am inferring rather than quoting, I will say so.

The One Sentence in the Statute Nobody Quotes

Start with the statute, because everything else hangs on it. Section 802(16) defines marihuana broadly: all parts of the Cannabis sativa L. plant, growing or not, its seeds, its resin, and preparations of those. The exclusions come after. They cover mature stalks, fiber made from them, oil or cake made from the seeds, and the sterilized seed of the plant which is incapable of germination.

The documented consequence is that the seed exclusion is narrow and turns entirely on viability. It does not carve out seed as a category. It carves out seed that has been rendered unable to sprout. A seed that can germinate falls outside the exclusion and sits inside the definition of the plant itself.

Clones are simpler still. Cuttings and rooted plantlets are live plant material, and no exclusion mentions them at all.

Keep this apart from the 2018 Farm Bill. That law removed hemp, meaning cannabis with no more than 0.3% delta-9 THC, from the definition. It is a different carve-out, built on a THC threshold rather than on sterilization, and it is not the argument here. A seed from a high-THC medical cultivar does not benefit from it.

One practical habit before going further: do not trust anyone's paraphrase of the clause, including mine. Pull the current text from uscode.house.gov or law.cornell.edu and read the whole of subparagraph (B) yourself. The wording is short, and the argument depends on its exact words.

What the April 2026 Order Actually Covers

The primary texts are the DOJ Office of Public Affairs announcement of April 23-24, 2026 and the Federal Register notice of April 28, 2026, titled Schedules of Controlled Substances: Rescheduling of Marijuana. Going by the announcement and the idea material behind this piece, the action places state-licensed medical marijuana in Schedule III. I am deliberately not reproducing the scope language here, because I have not been able to check the exact wording and will not paraphrase it as though it were a quote. Open the notice and read its scope definition word for word.

Then read it for one question. Does the scope language name plants, seeds, clones or propagation material, or does it speak only of products and dispensing activity? That is the whole matter. If the text names propagation material, the argument below changes. If it speaks only of the finished medical product and the activity of supplying it, the seed question is open.

Where the text is silent on seed, say so plainly. Silence is a fact about the document. Everything I say after that point is inference, and I will mark it as inference.

It also helps to keep the separate FDA-approved-products track out of the picture. That is its own action with its own Federal Register notice, covering FDA-approved products containing marijuana. Mixing the two is easy, since both are described as rescheduling, but they have different scope. A reader who sees Schedule III in a headline should ask which action is being described.

One more reading habit. Check whether the order speaks of marijuana as a substance, or of a defined class of state-licensed activity. The difference decides whether an upstream input like seed is reached through the substance definition or has to be named separately.

Walking the Genetics Chain Link by Link

The easiest way to see the gap is to walk the supply chain from the front. The links are a seed breeder or bank, a licensed cultivator, a mother plant, a clone, a flowering crop, a processor and a dispensary. The table sets out how I would sort each one. The right-hand column is my reading, not a quotation from the order.

The two links where the gap bites hardest are viable seed bought from a seed bank and clones passed between two licensees. Both are live genetic material crossing a transaction boundary, and both fall inside the definition. Neither is the finished product that most of the headlines had in mind.

Dispensing sits at the far end of the chain. That is exactly where coverage has concentrated, and it is the least ambiguous link.

A caution on one point. A state license makes an activity lawful under state law. It does not by itself answer the federal question for upstream inputs. Those are separate layers, and the order's text has to carry the federal one.

The Strongest Objection: Read the Order for Its Purpose

The strongest objection goes like this. An order that covers state-licensed medical marijuana must implicitly cover the plants that become it. Otherwise the rule would be incoherent: a federally recognized product made from a plant that is still Schedule I at every earlier step. On that purposive reading, propagation material rides along.

I take that seriously, and it may well be how regulators eventually read it. But my reply is that scheduling attaches to the statutory definition, and a purposive reading is a bet on how an agency will later interpret the text. It is not something in the text. A licensee who relies on it carries the risk if the interpretation goes the other way.

There is also a pattern in how the agency draws lines. Seedtiva's earlier piece, DEA Tells Medical Cannabis Operators: Trade Only With Registrants, showed the DEA building supply-chain boundaries through registration. If registration is how the agency sorts who may handle what, then a gap in who may handle genetics is the kind of thing it would be expected to fill by rule, not leave to implication.

The hearing track is unfinished. The DEA's rescheduling actions page was updated around November 6, and the DEA filed its final brief in the hearing on November 9, 2026, according to a Marijuana Moment newsletter. That is a secondary write-up, so go to the briefs themselves and check what they say about scope.

What would settle the question is short. Explicit language on seed and clones in a final rule would do it. So would DEA guidance addressing propagation material, or a written answer to a specific registrant. Until one of those exists, my read is that the purposive argument is plausible but unproven.

What to Ask a Regulator or Counsel Before Relying on It

Here is the short list I would take to a regulator or to counsel. Get the answers in writing where you can.

1. Does the order's text cover viable seed, clones, tissue culture and pollen, or only finished products and dispensing?
2. Does it cover transfers between licensees, or only sales to patients?
3. Is DEA registration required for cultivators and upstream suppliers, and must a seed seller hold one?
4. How does your state regulator's seed-to-sale tracking treat genetics that cross state lines?
5. Are imported genetics treated differently from domestic transfers?

The first two questions are about the text and can be answered from the order itself. The third depends on how the agency's registration requirements apply, and the earlier registrant piece is a good place to start. The fourth is a state question and varies by program. The fifth is a separate analysis, because import raises its own layer of rules.

Before moving genetics across a program line, get a written opinion from cannabis counsel who has read the order and the notice. An email from a state compliance officer saying it should be fine is not the same thing. I am not giving legal advice here. I am telling you which questions the headlines have left unanswered, and that answers should come from someone who can be held to them.

Why Seed Quality Standards Will Matter Next

It is worth looking at what comes after the gap closes. Seedtiva's piece on what it would take to certify cannabis seed made the point that once genetics are treated as a regulated input, certification and provenance questions follow. Schedule III treatment, even partial, pushes in that direction. A regulated input needs an origin, a lineage and a record.

Now the inference, labeled as such. A gap at the front of a supply chain tends to get noticed after the first enforcement action or audit question, not before. Nothing in the record I have checked says that has happened here. I am describing how these gaps usually surface, not predicting a specific event.

The practical step is cheap and available today. Keep records of where each set of genetics came from, the dates, and the licensee counterpart on each side of a transfer. If a regulator ever asks how a cultivar entered your facility, those records are the evidence.

If the order turns out to reach propagation material, the records cost you nothing. If it does not, they are the best protection you have.

The gap is answerable. The DOJ announcement and the Federal Register notice are public, and the deciding question is concrete: does the text name seed and clones? What anyone expects it to mean, or what a purposive reading might one day supply, is a different thing.

Until a regulator says in writing that propagation material is covered, treat viable genetics as the least settled link in the chain and plan transfers accordingly. That means asking the questions, keeping the records and not letting a dispensary-focused headline stand in for the statute.

Browse our seed collection.